Clinical trial
Temozolomide in Treating Patients With Progressive Low-Grade Glioma
NCT00003466 · Duke University, Other · Completed
Key facts
| NCT number | NCT00003466 |
|---|---|
| Title | Temozolomide in Treating Patients With Progressive Low-Grade Glioma |
| Official title | Phase II Treatment of Adults and Children With Progressive Low Grade Gliomas With Temodal |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 100 |
| Start date | Mar 1, 1998 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: